| Year |
Citation |
Score |
| 2017 |
Bate-Eya LT, Gierman HJ, Ebus ME, Koster J, Caron HN, Versteeg R, Dolman ME, Molenaar JJ. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. European Journal of Cancer (Oxford, England : 1990). 75: 63-72. PMID 28214660 DOI: 10.1016/J.Ejca.2016.12.019 |
0.35 |
|
| 2016 |
Bate-Eya LT, den Hartog IJ, van der Ploeg I, Schild L, Koster J, Santo EE, Westerhout EM, Versteeg R, Caron HN, Molenaar JJ, Dolman ME. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. Oncotarget. PMID 27056887 DOI: 10.18632/Oncotarget.8547 |
0.316 |
|
| 2016 |
van Wezel EM, Decarolis B, Stutterheim J, Zappeij-Kannegieter L, Berthold F, Schumacher-Kuckelkorn R, Simon T, Fiocco M, van Noesel MM, Caron HN, van der Schoot CE, Hero B, Tytgat GA. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients. European Journal of Cancer (Oxford, England : 1990). 54: 149-158. PMID 26796600 DOI: 10.1016/J.Ejca.2015.11.007 |
0.309 |
|
| 2016 |
Bate-Eya LT, Hartog IJMd, Ploeg Ivd, Schild L, Koster J, Versteeg R, Caron HN, Molenaar JJ, Dolman MEM. Abstract B09: MCL-1 inhibition improves ABT199 efficacy for BCL-2-dependent neuroblastoma Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-B09 |
0.34 |
|
| 2016 |
Eleveld TF, Schild L, Ebus ME, Sluis PGv, Westerhout EM, Caron HN, Koster JJB, Versteeg R, Molenaar JJ. Abstract A31: Activation of the RAS-MAPK pathway in primary neuroblastoma tumors is associated with poor prognosis Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-A31 |
0.33 |
|
| 2015 |
Dolman ME, Poon E, Ebus ME, den Hartog IJ, van Noesel CJ, Jamin Y, Hallsworth A, Robinson SP, Petrie K, Sparidans RW, Kok RJ, Versteeg R, Caron HN, Chesler L, Molenaar JJ. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26202950 DOI: 10.1158/1078-0432.Ccr-15-0313 |
0.355 |
|
| 2015 |
Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, ... ... Caron HN, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics. PMID 26121087 DOI: 10.1038/Ng.3333 |
0.308 |
|
| 2015 |
Kraal KC, Tytgat GA, van Eck-Smit BL, Kam B, Caron HN, van Noesel M. Upfront treatment of high-risk neuroblastoma with a combination of (131) I-MIBG and Topotecan. Pediatric Blood & Cancer. 62: 1886-91. PMID 25981988 DOI: 10.1002/Pbc.25580 |
0.327 |
|
| 2015 |
Ariës IM, van den Dungen RE, Koudijs MJ, Cuppen E, Voest E, Molenaar JJ, Caron HN, Pieters R, den Boer ML. Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance. Haematologica. 100: e132-6. PMID 25480501 DOI: 10.1182/Blood.V124.21.372.372 |
0.305 |
|
| 2015 |
van Wezel EM, Zwijnenburg D, Zappeij-Kannegieter L, Bus E, van Noesel MM, Molenaar JJ, Versteeg R, Fiocco M, Caron HN, van der Schoot CE, Koster J, Tytgat GA. Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma. The Journal of Molecular Diagnostics : Jmd. 17: 43-52. PMID 25445214 DOI: 10.1016/J.Jmoldx.2014.09.005 |
0.322 |
|
| 2014 |
Bate-Eya LT, Ebus ME, Koster J, den Hartog IJ, Zwijnenburg DA, Schild L, van der Ploeg I, Dolman ME, Caron HN, Versteeg R, Molenaar JJ. Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. European Journal of Cancer (Oxford, England : 1990). 50: 628-37. PMID 24321263 DOI: 10.1016/J.Ejca.2013.11.015 |
0.329 |
|
| 2014 |
Noesel MMv, Kraal KC, Kraker Jd, Eck-Smit BLv, Tytgat GA, Caron HN. Abstract B72: Upfront treatment of high-risk neuroblastoma with 131I-MIBG therapy and Topotecan. A phase II pilot window study (AMRO-NB-HR-2000/01) Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B72 |
0.307 |
|
| 2014 |
Eleveld TF, Schild L, Koster J, Zwijnenburg D, Ebus ME, van PS, Schulte JH, Caron HN, Versteeg R, Molenaar JJ. Abstract B41: Whole genome sequencing identifies tumor evolution events in relapse neuroblastoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B41 |
0.335 |
|
| 2012 |
Lamers F, Schild L, Koster J, Speleman F, Øra I, Westerhout EM, van Sluis P, Versteeg R, Caron HN, Molenaar JJ. Identification of BIRC6 as a novel intervention target for neuroblastoma therapy. Bmc Cancer. 12: 285. PMID 22788920 DOI: 10.1186/1471-2407-12-285 |
0.361 |
|
| 2012 |
Lamers F, Schild L, den Hartog IJ, Ebus ME, Westerhout EM, Ora I, Koster J, Versteeg R, Caron HN, Molenaar JJ. Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth. European Journal of Cancer (Oxford, England : 1990). 48: 3093-103. PMID 22366560 DOI: 10.1016/J.Ejca.2012.01.037 |
0.32 |
|
| 2012 |
Besançon OG, Tytgat GA, Meinsma R, Leen R, Hoebink J, Kalayda GV, Jaehde U, Caron HN, van Kuilenburg AB. Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids. Cancer Letters. 319: 23-30. PMID 22182450 DOI: 10.1016/J.Canlet.2011.12.016 |
0.308 |
|
| 2012 |
Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, Tytgat GA, van der Schoot CE. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 808-14. PMID 22142825 DOI: 10.1158/1078-0432.Ccr-11-0849 |
0.321 |
|
| 2012 |
Lamers F, Schild L, Koster J, Versteeg R, Caron HN, Molenaar JJ. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. European Journal of Cancer (Oxford, England : 1990). 48: 763-71. PMID 22088485 DOI: 10.1016/J.Ejca.2011.10.012 |
0.331 |
|
| 2012 |
Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, Gisselsson D, Øra I, Speleman F, Caron HN, Versteeg R. Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes, Chromosomes & Cancer. 51: 10-9. PMID 22034077 DOI: 10.1002/Gcc.20926 |
0.364 |
|
| 2012 |
Santo EE, Ebus ME, Koster J, Schulte JH, Lakeman A, van Sluis P, Vermeulen J, Gisselsson D, Øra I, Lindner S, Buckley PG, Stallings RL, Vandesompele J, Eggert A, Caron HN, et al. Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene. 31: 1571-81. PMID 21860421 DOI: 10.1038/Onc.2011.344 |
0.37 |
|
| 2011 |
Lamers F, van der Ploeg I, Schild L, Ebus ME, Koster J, Hansen BR, Koch T, Versteeg R, Caron HN, Molenaar JJ. Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocrine-Related Cancer. 18: 657-68. PMID 21859926 DOI: 10.1530/Erc-11-0207 |
0.36 |
|
| 2010 |
De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, ... ... Caron H, et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4353-62. PMID 20719933 DOI: 10.1158/1078-0432.Ccr-09-2660 |
0.319 |
|
| 2010 |
Fardin P, Barla A, Mosci S, Rosasco L, Verri A, Versteeg R, Caron HN, Molenaar JJ, Ora I, Eva A, Puppo M, Varesio L. A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Molecular Cancer. 9: 185. PMID 20624283 DOI: 10.1186/1476-4598-9-185 |
0.353 |
|
| 2010 |
Geerts D, Koster J, Albert D, Koomoa DL, Feith DJ, Pegg AE, Volckmann R, Caron H, Versteeg R, Bachmann AS. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. International Journal of Cancer. 126: 2012-24. PMID 19960435 DOI: 10.1002/Ijc.25074 |
0.353 |
|
| 2009 |
Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, Westerhout EM, Versteeg R, Caron HN. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 106: 12968-73. PMID 19525400 DOI: 10.1073/Pnas.0901418106 |
0.377 |
|
| 2009 |
Caron HN, Westerhout EM, Molenaar JJ, den MLB, Clifford SC, Delattre O, Geoerger B, Lanvers C, Pietsch T, Scotlandi K, Sera M, Shipley J, Vassal G, Versteeg R, Verschuur A. Abstract C116: The KidsCancerKinome: Validation of drug targets for high risk childhood cancers Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C116 |
0.319 |
|
| 2009 |
Westerhout EM, Kool M, Molenaar JJ, den MLB, Clifford SC, Delattre O, Geoerger B, Lanvers C, Pietsch T, Serra M, Shipley J, Vassal G, Versteeg R, Verschuur AC, Caron HN. Abstract C115: The KidsCancerKinome: Validation of Aurora kinases as potential drug targets in pediatric tumors Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C115 |
0.333 |
|
| 2009 |
Molenaar JJ, Westerhout EM, den MLB, Clifford SC, Delattre O, Geoerger B, Lanvers C, Pietsch T, Serra M, Shipley J, Vassal G, Versteeg R, Verschuur AC, Caron HN. Abstract C114: The KidsCancerKinome: Validation of CDK2 as potential drug target in pediatric tumors Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C114 |
0.351 |
|
| 2008 |
Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, Mrsić A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. Plos One. 3: e3088. PMID 18769486 DOI: 10.1371/Journal.Pone.0003088 |
0.324 |
|
| 2008 |
Cuperus R, Tytgat GA, Leen R, Brites P, Bras J, Caron HN, Van Kuilenburg AB. Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids. International Journal of Oncology. 32: 1011-9. PMID 18425327 DOI: 10.3892/Ijo.32.5.1011 |
0.314 |
|
| 2008 |
Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJ, Versteeg R, Caron HN. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Research. 68: 2599-609. PMID 18413728 DOI: 10.1158/0008-5472.Can-07-5032 |
0.318 |
|
| 2008 |
Merks JH, Ozgen HM, Koster J, Zwinderman AH, Caron HN, Hennekam RC. Prevalence and patterns of morphological abnormalities in patients with childhood cancer. Jama. 299: 61-9. PMID 18167407 DOI: 10.1001/Jama.2007.66 |
0.327 |
|
| 2008 |
Koppen A, Ait-Aissa R, Koster J, Øra I, Bras J, Van Sluis PG, Caron H, Versteeg R, Valentijn LJ. Dickkopf-3 expression is a marker for neuroblasts tumor maturation and is down-regulated by MYCN International Journal of Cancer. 122: 1455-1464. PMID 18059033 DOI: 10.1002/Ijc.23180 |
0.347 |
|
| 2007 |
Koppen A, Ait-Aissa R, Koster J, van Sluis PG, Ora I, Caron HN, Volckmann R, Versteeg R, Valentijn LJ. Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma. European Journal of Cancer (Oxford, England : 1990). 43: 2413-22. PMID 17826980 DOI: 10.1016/J.Ejca.2007.07.024 |
0.328 |
|
| 2006 |
De Ruijter AJM, Leen R, Hoebink J, Caron HN, Van Kuilenburg ABP. Antagonistic effects of sequential administration of BL1521, a histone deacetylase inhibitor, and gemcitabine to neuroblastoma cells Cancer Letters. 233: 240-246. PMID 15907366 DOI: 10.1016/J.Canlet.2005.03.016 |
0.313 |
|
| 2006 |
Voûte P, Barrett A, Tevens M, Caron H. Cancer in children. Clinical management MéDecine Palliative : Soins De Support - Accompagnement - éThique. 5: 225. DOI: 10.1016/S1636-6522(06)74277-5 |
0.517 |
|
| 2005 |
de Ruijter AJ, Meinsma RJ, Bosma P, Kemp S, Caron HN, van Kuilenburg AB. Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma. Experimental Cell Research. 309: 451-67. PMID 16084510 DOI: 10.1016/J.Yexcr.2005.06.024 |
0.345 |
|
| 2005 |
Ouwehand K, De Ruijter AJM, Van Bree C, Caron HN, Van Kuilenburg ABP. Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins Febs Letters. 579: 1523-1528. PMID 15733867 DOI: 10.1016/J.Febslet.2005.01.058 |
0.308 |
|
| 2004 |
Van Limpt V, Schramm A, Lakeman A, Van Sluis P, Chan A, Van Noesel M, Baas F, Caron H, Eggert A, Versteeg R. The Phox2B homeobox gene is mutated in sporadic neuroblastomas Oncogene. 23: 9280-9288. PMID 15516980 DOI: 10.1038/Sj.Onc.1208157 |
0.313 |
|
| 2004 |
De Ruijter AJM, Kemp S, Kramer G, Meinsma RJ, Kaufmann JO, Caron HN, Van Kuilenburg ABP. The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells Biochemical Pharmacology. 68: 1279-1288. PMID 15345317 DOI: 10.1016/J.Bcp.2004.05.010 |
0.325 |
|
| 2003 |
Van Limpt VAE, Chan AJ, Van Sluis PG, Caron HN, Van Noesel CJM, Versteeg R. High delta-like 1 expression in a subset of neuroblastoma cell lines corresponds to a differentiated chromaffin cell type International Journal of Cancer. 105: 61-69. PMID 12672031 DOI: 10.1002/Ijc.11047 |
0.341 |
|
| 2003 |
Molenaar JJ, Van Sluis P, Boon K, Versteeg R, Caron HN. Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma Genes Chromosomes and Cancer. 36: 242-249. PMID 12557224 DOI: 10.1002/Gcc.10166 |
0.348 |
|
| 2002 |
Godfried MB, Veenstra M, Valent A, Sluis Pv, Voûte PA, Versteeg R, Caron HN. Lack of interstitial chromosome 1p deletions in clinically-detected neuroblastoma. European Journal of Cancer (Oxford, England : 1990). 38: 1513-9. PMID 12110498 DOI: 10.1016/S0959-8049(02)00137-5 |
0.342 |
|
| 2002 |
Godfried MB, Veenstra M, Sluis PV, Boon K, Asperen RV, Hermus MC, Schaik BDCV, Voûte TPA, Schwab M, Versteeg R, Caron HN. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2 Oncogene. 21: 2097-2101. PMID 11960382 DOI: 10.1038/Sj.Onc.1205259 |
0.335 |
|
| 2001 |
Spieker N, Beitsma M, Van Sluis P, Chan A, Caron H, Versteeg R. Three chromosomal rearrangements in neuroblastoma cluster within a 300-kb region on 1p36.1 Genes Chromosomes and Cancer. 31: 172-181. PMID 11319804 DOI: 10.1002/Gcc.1130 |
0.353 |
|
| 2001 |
Boon K, Caron HN, van Asperen R, Valentijn L, Hermus MC, van Sluis P, Roobeek I, Weis I, Voûte PA, Schwab M, Versteeg R. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. The Embo Journal. 20: 1383-93. PMID 11250904 DOI: 10.1093/Emboj/20.6.1383 |
0.336 |
|
| 2001 |
Caron H, van Schaik B, van der Mee M, Baas F, Riggins G, van Sluis P, Hermus MC, van Asperen R, Boon K, Voûte PA, Heisterkamp S, van Kampen A, Versteeg R. The human transcriptome map: clustering of highly expressed genes in chromosomal domains. Science (New York, N.Y.). 291: 1289-92. PMID 11181992 DOI: 10.1126/Science.1056794 |
0.309 |
|
| 2001 |
Spieker N, Van Sluis P, Beitsma M, Boon K, Van Schaik BDC, Van Kampen AHC, Caron H, Versteeg R. The MEIS1 oncogene is highly expressed in neuroblastoma and amplified in cell line IMR32 Genomics. 71: 214-221. PMID 11161815 DOI: 10.1006/Geno.2000.6408 |
0.356 |
|
| 2001 |
Caron H, Spieker N, Godfried M, Veenstra M, Van Sluis P, De Kraker J, Vote P, Versteeg R. Chromosome bands 1p35-36 contain two distinct neuroblastoma tumor suppressor loci, one of which is imprinted Genes Chromosomes and Cancer. 30: 168-174. PMID 11135433 DOI: 10.1002/1098-2264(200102)30:2<168::Aid-Gcc1072>3.0.Co;2-E |
0.372 |
|
| 2000 |
Van Limpt V, Chan A, Caron H, Van Sluis P, Boon K, Hermus MC, Versteeg R. SAGE analysis of neuroblastoma reveals a high expression of the human homologue of the Drosophila Delta gene Medical and Pediatric Oncology. 35: 554-558. PMID 11107116 DOI: 10.1002/1096-911X(20001201)35:6<554::Aid-Mpo13>3.0.Co;2-R |
0.322 |
|
| 2000 |
Spieker N, Beitsma M, Sluis Pv, Roobeek I, Dunnen JTd, Speleman F, Caron H, Versteeg R. An integrated 5-Mb physical, genetic, and radiation hybrid map of a 1p36.1 region implicated in neuroblastoma pathogenesis. Genes, Chromosomes and Cancer. 27: 143-152. PMID 10612802 DOI: 10.1002/(Sici)1098-2264(200002)27:2<143::Aid-Gcc5>3.0.Co;2-E |
0.354 |
|
| 1996 |
Hofstra RM, Cheng NC, Hansen C, Stulp RP, Stelwagen T, Clausen N, Tommerup N, Caron H, Westerveld A, Versteeg R, Buys CH. No mutations found by RET mutation scanning in sporadic and hereditary neuroblastoma. Human Genetics. 97: 362-4. PMID 8786083 DOI: 10.1007/Bf02185773 |
0.546 |
|
| 1996 |
Caron H, van Sluis P, Buschman R, Pereira do Tanque R, Maes P, Beks L, de Kraker J, Voûte PA, Vergnaud G, Westerveld A, Slater R, Versteeg R. Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus. Human Genetics. 97: 834-7. PMID 8641706 DOI: 10.1007/Bf02346199 |
0.582 |
|
| 1996 |
Caron H, van Sluis P, de Kraker J, Bökkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voûte PA, Versteeg R. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. The New England Journal of Medicine. 334: 225-30. PMID 8531999 DOI: 10.1056/Nejm199601253340404 |
0.536 |
|
| 1995 |
Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma Medical and Pediatric Oncology. 24: 215-221. PMID 7700165 DOI: 10.1002/Mpo.2950240402 |
0.375 |
|
| 1995 |
Caron H, Peter M, van Sluis P, Speleman F, de Kraker J, Laureys G, Michon J, Brugières L, Voûte PA, Westerveld A. Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. Human Molecular Genetics. 4: 535-9. PMID 7633401 DOI: 10.1093/Hmg/4.4.535 |
0.583 |
|
| 1995 |
Versteeg R, Caron H, Cheng NC, van der Drift P, Slater R, Westerveld A, Voûte PA, Delattre O, Laureys G, Van Roy N. 1p36: every subband a suppressor? European Journal of Cancer (Oxford, England : 1990). 31: 538-41. PMID 7576962 DOI: 10.1016/0959-8049(95)00037-J |
0.523 |
|
| 1994 |
Ngan Ching C, Caron H, Chan A, Beitsma M, van Sluis P, Speleman F, Westerveld A, Versteeg R. N-myc regulation in neuroblastoma Cancer Genetics and Cytogenetics. 77: 175. DOI: 10.1016/0165-4608(94)90335-2 |
0.514 |
|
| 1993 |
Caron H, van Sluis P, van Hoeve M, de Kraker J, Bras J, Slater R, Mannens M, Voûte PA, Westerveld A, Versteeg R. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. Nature Genetics. 4: 187-90. PMID 8102298 DOI: 10.1038/Ng0693-187 |
0.684 |
|
| 1993 |
Caron H, Sluis Pv, Hoeve Mv, Kraker Jd, Bras J, Slater R, Mannens M, Voûte PA, Westerveld A, Versteeg R. Erratum: Corrigendum: Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification Nature Genetics. 4: 431-431. DOI: 10.1038/Ng0893-431A |
0.563 |
|
| 1992 |
Versteeg R, Caron H, van Sluis P, Chan A, van Roy N, Cheng NC, Mannens M, Laurey G, Slater R, Speleman F, Westerveld A. Tumor suppressor genes in neuroblastoma Cancer Genetics and Cytogenetics. 63: 169. DOI: 10.1016/0165-4608(92)90516-B |
0.534 |
|
| Show low-probability matches. |
